• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative effectiveness review of antiplatelet agents in peripheral artery disease.

作者信息

Schmit Kristine, Dolor Rowena J, Jones W Schuyler, Vemulapalli Sreekanth, Hasselblad Victor, Subherwal Sumeet, Heidenfelder Brooke, Patel Manesh R

机构信息

Department of Community and Family Medicine, Duke University School of Medicine, Durham, NC (K.S.) Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (K.S., R.J.D., S.J., M.R.P.).

Division of General Internal Medicine, Duke University Medical Center, Durham, NC (R.J.D.) Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (K.S., R.J.D., S.J., M.R.P.) Duke Evidence-based Practice Center, Duke Clinical Research Institute, Duke University, Durham, NC (R.J.D., B.H.).

出版信息

J Am Heart Assoc. 2014 Dec 4;3(6):e001330. doi: 10.1161/JAHA.113.001330.

DOI:10.1161/JAHA.113.001330
PMID:25477329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4338727/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/b9c727197959/jah3-3-e001330-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/fdc2a98aa4eb/jah3-3-e001330-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/f11e2c76102e/jah3-3-e001330-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/71fa82031031/jah3-3-e001330-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/b9c727197959/jah3-3-e001330-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/fdc2a98aa4eb/jah3-3-e001330-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/f11e2c76102e/jah3-3-e001330-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/71fa82031031/jah3-3-e001330-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a3/4338727/b9c727197959/jah3-3-e001330-g4.jpg

相似文献

1
Comparative effectiveness review of antiplatelet agents in peripheral artery disease.外周动脉疾病中抗血小板药物的比较有效性评价
J Am Heart Assoc. 2014 Dec 4;3(6):e001330. doi: 10.1161/JAHA.113.001330.
2
Review of aspirin and clopidogrel resistance in peripheral arterial disease.外周动脉疾病中阿司匹林和氯吡格雷抵抗的综述。
J Vasc Surg. 2017 Nov;66(5):1576-1586. doi: 10.1016/j.jvs.2017.07.065.
3
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.抗血栓治疗综述以及外周动脉疾病（ePAD）患者中随机使用依度沙班试验的基本原理和设计：在股腘动脉血管腔内介入术后，将依度沙班或氯吡格雷添加至阿司匹林治疗。
J Endovasc Ther. 2015 Apr;22(2):261-8. doi: 10.1177/1526602815574687.
4
Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.经皮腔内血管治疗的外周动脉疾病患者双联抗血小板治疗与单药抗血小板治疗的随机对照试验 12 个月结果。
J Endovasc Ther. 2013 Oct;20(5):699-706. doi: 10.1583/13-4275MR.1.
5
Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.患有严重肢体缺血的外周动脉闭塞性疾病患者对双重抗血小板治疗的反应。
Clin Lab. 2014;60(10):1601-7. doi: 10.7754/clin.lab.2013.131007.
6
Inhibition of platelet function with clopidogrel is associated with a reduction of inflammation in patients with peripheral artery disease.氯吡格雷抑制血小板功能与外周动脉疾病患者炎症反应的减轻相关。
Cardiovasc Revasc Med. 2016 Apr-May;17(3):169-75. doi: 10.1016/j.carrev.2016.01.010. Epub 2016 Mar 9.
7
High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.外周动脉疾病患者经皮血管腔内介入治疗后高治疗期血小板反应性及预后
Vasa. 2016;45(2):155-61. doi: 10.1024/0301-1526/a000510.
8
Barriers of antiaggregant treatment.抗血小板治疗的障碍。
Rev Med Chir Soc Med Nat Iasi. 2014 Apr-Jun;118(2):333-8.
9
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?外周动脉疾病患者的联合抗血小板治疗：最佳治疗方案是阿司匹林、氯吡格雷还是两者联用？
Catheter Cardiovasc Interv. 2009 Jul 1;74 Suppl 1:S1-6. doi: 10.1002/ccd.21995.
10
[New antiplatelet agents (platelet receptor blockers): has aspirin come out of place?].[新型抗血小板药物（血小板受体阻滞剂）：阿司匹林是否已过时？]
Praxis (Bern 1994). 2004 Jun 2;93(23):1003-5. doi: 10.1024/0369-8394.93.23.1003.

引用本文的文献

1
Polypills in the Management of Cardiovascular Risk-A Perspective.心血管风险管理中的复方制剂——一种观点
J Clin Med. 2024 Sep 16;13(18):5487. doi: 10.3390/jcm13185487.
2
Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice.依替巴肽，一种具有新适应证的老治疗性肽：从临床药理学到日常临床实践。
Int J Mol Sci. 2023 Mar 13;24(6):5446. doi: 10.3390/ijms24065446.
3
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

本文引用的文献

1
Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.外周动脉疾病患者应用Vorapaxar：TRA2°P-TIMI 50 研究结果。
Circulation. 2013 Apr 9;127(14):1522-9, 1529e1-6. doi: 10.1161/CIRCULATIONAHA.112.000679. Epub 2013 Mar 15.
2
Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial.采用单药或双联抗血小板治疗的外周动脉介入治疗管理——MIRROR 研究：一项随机、双盲临床试验。
Eur Radiol. 2012 Sep;22(9):1998-2006. doi: 10.1007/s00330-012-2441-2. Epub 2012 May 10.
3
Antiplatelet agents for intermittent claudication.
2016 AHA/ACC 指南：下肢外周动脉疾病患者管理——美国心脏病学会/美国心脏协会实践指南工作组的报告。
Circulation. 2017 Mar 21;135(12):e726-e779. doi: 10.1161/CIR.0000000000000471. Epub 2016 Nov 13.
4
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2016 年美国心脏协会/美国心脏病学会下肢外周动脉疾病管理指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
Circulation. 2017 Mar 21;135(12):e686-e725. doi: 10.1161/CIR.0000000000000470. Epub 2016 Nov 13.
用于间歇性跛行的抗血小板药物。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD001272. doi: 10.1002/14651858.CD001272.pub2.
4
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.随机、安慰剂对照氯吡格雷和阿司匹林在周围动脉疾病旁路手术中的应用（CASPAR）试验结果。
J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2. doi: 10.1016/j.jvs.2010.04.027. Epub 2010 Aug 1.
5
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.稳定血管疾病或血管疾病风险因素患者的双联抗血小板治疗出血并发症：来自氯吡格雷用于高动脉血栓形成风险及缺血稳定性、管理和预防（CHARISMA）试验的结果。
Circulation. 2010 Jun 15;121(23):2575-83. doi: 10.1161/CIRCULATIONAHA.109.895342. Epub 2010 Jun 1.
6
Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.阿司匹林用于筛查低踝臂指数的一般人群预防心血管事件：一项随机对照试验。
JAMA. 2010 Mar 3;303(9):841-8. doi: 10.1001/jama.2010.221.
7
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.阿司匹林用于预防外周动脉疾病患者心血管事件：随机试验的荟萃分析
JAMA. 2009 May 13;301(18):1909-19. doi: 10.1001/jama.2009.623.
8
Patients with peripheral arterial disease in the CHARISMA trial.CHARISMA试验中的外周动脉疾病患者。
Eur Heart J. 2009 Jan;30(2):192-201. doi: 10.1093/eurheartj/ehn534. Epub 2009 Jan 9.
9
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.预防动脉疾病和糖尿病进展（POPADAD）试验：糖尿病和无症状外周动脉疾病患者中阿司匹林和抗氧化剂的析因随机安慰剂对照试验。
BMJ. 2008 Oct 16;337:a1840. doi: 10.1136/bmj.a1840.
10
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.在CHARISMA试验中曾患心肌梗死、中风或有症状性外周动脉疾病的患者。
J Am Coll Cardiol. 2007 May 15;49(19):1982-8. doi: 10.1016/j.jacc.2007.03.025. Epub 2007 Apr 11.